Additional explanation for lack of pharmacodynamic interaction between atazanavir and buprenorphine reported by Vergara-Rodriquez et al.
Robert Douglas
RD
Bruce
D019380:Anti-HIV Agents / Q000494:pharmacology*; D002047:Buprenorphine / Q000009:adverse effects* / Q000627:therapeutic use*; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology*; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D009270:Naloxone / Q000009:adverse effects* / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000150:complications*
D019380:Anti-HIV Agents; D009270:Naloxone; D002047:Buprenorphine